The newly unveiled 2018 Canadian federal budget announced on Tuesday (February 27) offers cannabis investors a closer look into how the legal product will be taxed in the future.

Delivered by Finance Minister Bill Morneau, the document called “Equality + Growth, A Strong Middle Class,” presented all the spending done by the federal government to regulate the cannabis industry.


The budget indicates an excise duty framework is being proposed for the majority of cannabis products set to be available to consumers after the legalization of cannabis becomes official later this year.

Cannabis products with low amounts of tetrahydrocannabinol (THC) will not be taxed. Neither will pharmaceutical items derived from cannabis, as long as they have a Drug Identification Number and are only available to patients with a prescription.

Taxing for cannabis products will come down to two options: whichever is the highest applicable per product, either a $1 per gram standard or 10 percent of a product price.

The budget said:

“Under the framework, excise duties will be imposed on federally licensed producers at the higher of a flat rate applied on the quantity of cannabis contained in a final product, or a percentage of the sale price of the product sold by a federal licensee.

The proposed tax will kick off once sales of recreational cannabis become available in retail.

Patient advocacy group ‘outraged’ over budget proposals

A cannabis patients advocacy group, however, expressed disappointment on the Canadian budget. Canadians for Fair Access to Medical Marijuana (CFAMM) issued a statement saying they were “outraged” to find out the limits of the products that won’t be taxed.

CFAMM acknowledge the tax won’t affect products with low to no amounts of THC but said those products are actually a minority among the patient population and represent a small representation of use.

The government will exempt some products such as non-THC and low-THC medicine from the excise tax but those products represent a small minority of those used by patients. “It’s quite clear that Canadians understand that taxing medical cannabis is unfair and wrong,” Jonathan Zaid executive director of CFAMM stated.

“Exempting a small minority of patients does not address the affordability issue and implies some patients are more legitimate than others,” Zaid commented.

The actual breakdown of the tax will be split with 75 percent going to the Canadian provinces and territorial governments. The federal government will keep the remainder 25 percent. However, that sum will be capped annually at $100 million for the first two years after legalization.

All the extra money, in this case, will be sent back to the provinces as part of a special arrangement between the two levels of government. The arranged sums are expected to be delivered to municipalities and local communities due to, according to the budget, their role on “the front lines of legalization.”

Dan Kelly Dan Kelly president, CEO and chair Canadian Federation of Independent Business told Global News he is worried the government is asking for too much with this proposed tax.

“I think a smarter strategy would be to start with a very reasonable level of taxation to ensure that we get the business above ground before we start ratcheting it up,” he said.

A report on the entire budget prepared by business law firm Aird and Berlis indicated cannabis cultivators and manufacturers will now be required to get a license from Canada Revenue Agency (CRA) and “remit the excise duty, where applicable.”

Federal government will invest in cannabis research

The budget also included information on other areas related to the emerging cannabis industry the government plans to invest in. The Mental Health Commission will receive $10 million over five years to “assess the impact of cannabis use on the mental health of Canadians.”

Another $10 million, also over five years, will be given to the Canadian Centre on Substance Use and Addiction for research purposes.

It was also revealed how much will the government invest in the public education surrounding cannabis per year. Public education will get $18 million in 2018-2019, which then will go up to $16 million from the 2019-2020 cycle until the year 2023, resulting in a total $83 million campaign.

Investor Takeaway

Advocates of the industry have long argued for a complete removal of a tax on medical cannabis products. With the initial comments from CFAMM, it will be interesting to see how companies in the space react to their actions attempting to convince the government to remove the tax on medical products.

Observers of the cannabis space will also have to keep a close eye on the impact the tax on recreational products will have in deterring the illegal marijuana market.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less